These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 17683198)

  • 1. Development of new tuberculosis vaccines: a global perspective on regulatory issues.
    Brennan MJ; Fruth U; Milstien J; Tiernan R; de Andrade Nishioka S; Chocarro L;
    PLoS Med; 2007 Aug; 4(8):e252. PubMed ID: 17683198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.
    Dietrich J; Doherty TM
    APMIS; 2009 May; 117(5-6):440-57. PubMed ID: 19400867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host versus pathogen: two sides of the same challenge in the TB world.
    Cooper AM
    Eur J Immunol; 2009 Mar; 39(3):632-3. PubMed ID: 19283712
    [No Abstract]   [Full Text] [Related]  

  • 5. Tuberculosis vaccine research: the impact of immunology.
    Barker LF; Brennan MJ; Rosenstein PK; Sadoff JC
    Curr Opin Immunol; 2009 Jun; 21(3):331-8. PubMed ID: 19505813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design of vaccines against tuberculosis directed by basic immunology.
    Reece ST; Kaufmann SH
    Int J Med Microbiol; 2008 Jan; 298(1-2):143-50. PubMed ID: 17702652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving new vaccines for tuberculosis through the regulatory process.
    Brennan MJ
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S247-9. PubMed ID: 10875792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent findings in immunology give tuberculosis vaccines a new boost.
    Kaufmann SH
    Trends Immunol; 2005 Dec; 26(12):660-7. PubMed ID: 16246622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tuberculosis due to high-dose challenge in partially immune individuals: a problem for vaccination?
    Rook GA; Hernández-Pando R; Zumla A
    J Infect Dis; 2009 Mar; 199(5):613-8. PubMed ID: 19199549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety issues regarding new vaccines for tuberculosis, with an emphasis on post-exposure vaccination.
    Orme IM
    Tuberculosis (Edinb); 2006 Jan; 86(1):68-73. PubMed ID: 16260181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The challenges of developing new tuberculosis vaccines.
    Barker LF; Leadman AE; Clagett B
    Health Aff (Millwood); 2011 Jun; 30(6):1073-9. PubMed ID: 21653959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Driving a stake into resurgent TB.
    Enserink M
    Science; 2001 Jul; 293(5528):234-5. PubMed ID: 11452108
    [No Abstract]   [Full Text] [Related]  

  • 13. A courageous step down the road toward a new tuberculosis vaccine.
    Dockrell HM; Zhang Y
    Am J Respir Crit Care Med; 2009 Apr; 179(8):628-9. PubMed ID: 19351870
    [No Abstract]   [Full Text] [Related]  

  • 14. Propelling novel vaccines directed against tuberculosis through the regulatory process.
    Brennan MJ; Collins FM; Morris SL
    Tuber Lung Dis; 1999; 79(3):145-51. PubMed ID: 10656113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenge of developing new tuberculosis vaccines to generate life-long protective immunity.
    Triccas JA; Nambiar JK
    Expert Rev Vaccines; 2009 Jul; 8(7):823-5. PubMed ID: 19538108
    [No Abstract]   [Full Text] [Related]  

  • 16. Real vaccines in the real world: tuberculosis vaccines move south.
    Dockrell HM
    Expert Rev Vaccines; 2008 Aug; 7(6):703-7. PubMed ID: 18665767
    [No Abstract]   [Full Text] [Related]  

  • 17. Simplified deoxypropionate acyl chains for Mycobacterium tuberculosis sulfoglycolipid analogues: chain length is essential for high antigenicity.
    Gau B; Lemétais A; Lepore M; Garcia-Alles LF; Bourdreux Y; Mori L; Gilleron M; De Libero G; Puzo G; Beau JM; Prandi J
    Chembiochem; 2013 Dec; 14(18):2413-7. PubMed ID: 24174158
    [No Abstract]   [Full Text] [Related]  

  • 18. Tuberculosis vaccines: a strategic blueprint for the next decade.
    Brennan MJ; Thole J
    Tuberculosis (Edinb); 2012 Mar; 92 Suppl 1():S6-13. PubMed ID: 22441160
    [No Abstract]   [Full Text] [Related]  

  • 19. Tuberculosis vaccines - an update.
    Andersen P
    Nat Rev Microbiol; 2007 Jul; 5(7):484-7. PubMed ID: 17571458
    [No Abstract]   [Full Text] [Related]  

  • 20. Overcoming the global crisis: "yes, we can", but also for TB ... ?
    Ottenhoff TH
    Eur J Immunol; 2009 Aug; 39(8):2014-20. PubMed ID: 19672895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.